Citations

Clear

3030 citation(s) found for "Susan, M".

Borrelia mayonii sp. nov., a member of the Borrelia burgdorferi sensu lato complex, detected in patients and ticks in the upper midwestern United States
Pritt, Bobbi S. , Respicio-Kingry, Laurel, Sloan, Lynne M., Schriefer, Martin E., Replogle, Adam J., Bjork, Jenna , Liu, Gong‐Ping , Kingry, Luke C. , Mead, Paul S. , Neitzel, David F., Schiffman, Elizabeth , Johnson, Diep K. Hoang, Davis, Jeffrey P., Paskewitz, Susan M. , Boxrud, David, Deedon, Alecia, Lee, Xia , Miller, Tracy K., Feist, Michelle, Steward, Christopher R., Theel, Elitza S. , Patel, Robin , Irish, Cole L., Petersen, Jeannine M., Patel, Robin , Kingry, Luke , Pritt, Bobbi S

Mayo Clinic

International Journal of Systematic and Evolutionary Microbiology | August 24, 2016 | Volume: 66 | Issue: 11 | Pages: 4878-4880

10.1099/ijsem.0.001445 | PMID 27558626 Get It

Surgical Site Infections in Cancer Patients with Intrathecal Drug Delivery Devices
Scanlon, Maura M., Gazelka, Halena M. , Moeschler, Susan M. , Hoelzer, Bryan C. , Hooten, W. Michael , Bendel, Markus A. , Lamer, Tim J.

Mayo Clinic

Pain Medicine | August 22, 2016 | Volume: 18 | Issue: 3 | Pages: 520-525

10.1093/pm/pnw203 | PMID 27550951 Get It

Abstract Objectives. Our purpose was to determine the incidence of surgical site infection (SSI) in cancer patients receiving an intrathecal drug delivery system (IDDS) and compare that rate with the incidence of SSI in the general population receiving an IDDS or spinal cord stimulator. We attempted to describe risk factors for SSIs in cancer patients treated with IDDS in terms of exposure to cancer treatments. Design. Retrospective review. Setting. Large tertiary care center. Patients. Cancer patients receiving an IDDS in 2006–2013. Methods. The incidence of SSI was determined according to the US Centers for Disease Control and Prevention definition. Medication regimens and current cancer treatment were investigated to identify immunocompromised patients during IDDS placement. Microbacteriology, treatment, and overall outcomes were investigated. Results. Sixty-four patients had an IDDS implanted in 2006–2013. SSI developed in four patients (6.2%). All four patients had received chemotherapy or radiotherapy within three months before implantation. Three of the three were receiving dexamethasone, and three of the four required explantation of the IDDS. Conclusion. The incidence of SSI was at the upper end of the published infection rates for IDDS. The risk of SSI may be increased in this population because of factors that alter the patient’s immune status, including concomitant corticosteroid use, radiotherapy near the SSI, and presence of immunomodulators. The identification and mitigation of certain risk factors for this population may prevent infection in future patients.
Treatment of Refractory Postdural Puncture Headache after Intrathecal Drug Delivery System Implantation with Epidural Blood Patch Procedures: A 20-Year Experience
Bendel, Markus A. , Moeschler, Susan M. , Qu, Wenchun , Hanley, Eugerie, Neuman, Stephanie, Eldrige, Jason S. , Hoelzer, Bryan C. , Neuman, Stephanie A

Mayo Clinic

Pain Research and Treatment | August 11, 2016 | Volume: 2016 | Issue: No issue available | Pages: 1-5

10.1155/2016/2134959 | PMID 27597897 Get It

A recent publication reported the incidence of postdural puncture headache (PDPH) in conjunction with intrathecal drug delivery system (IDDS) implantation to be nearly 23 percent. Many patients responded to conservative measures but a percentage needed invasive treatment with an epidural blood patch (EBP). There is limited data to describe the technical details, success rates, and complications associated with EBP in this population. This study aims to provide a retrospective report of EBP for patients suffering from PDPH related to IDDS implantation. A chart review established a cohort of patients that required EBP in relation to a PDPH after IDDS implantation. This cohort was evaluated for demographic data as well as details of the EBP including technical procedural data, success rates, and complications. All patients received a trial of conservative therapy. Standard sterile technique and skin preparation were utilized with no infectious complications. The EBP was placed below the level of the IDDS catheter in 94% of procedures. Fluoroscopy was utilized in each case. The mean EBP volume was 18.6 cc and median time of EBP was day 7 after implant. There were no complications associated with EBP. EBP appears to be an effective intervention in this subset of PDPH patients.
2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis
Galgiani, John N. , Ampel, Neil M. , Blair, Janis E. , Catanzaro, Antonino , Geertsma, Francesca, Hoover, Susan E. , Johnson, Royce H. , Kusne, Shimon , Lisse, Jeffrey , MacDonald, Joel D., Meyerson, Shari L. , Raksin, P B , Siever, John, Stevens, David A. , Sunenshine, Rebecca, Siever, John, Theodore, Nicholas

Mayo Clinic

Clinical Infectious Diseases | July 28, 2016 | Volume: 63 | Issue: 6 | Pages: e112-e146

10.1093/cid/ciw360 | PMID 27470238 Get It

Abstract It is important to realize that guidelines cannot always account for individual variation among patients. They are not intended to supplant physician judgment with respect to particular patients or special clinical situations. Infectious Diseases Society of America considers adherence to these guidelines to be voluntary, with the ultimate determination regarding their application to be made by the physician in the light of each patient's individual circumstances. Coccidioidomycosis, also known as San Joaquin Valley fever, is a systemic infection endemic to parts of the southwestern United States and elsewhere in the Western Hemisphere. Residence in and recent travel to these areas are critical elements for the accurate recognition of patients who develop this infection. In this practice guideline, we have organized our recommendations to address actionable questions concerning the entire spectrum of clinical syndromes. These can range from initial pulmonary infection, which eventually resolves whether or not antifungal therapy is administered, to a variety of pulmonary and extrapulmonary complications. Additional recommendations address management of coccidioidomycosis occurring for special at-risk populations. Finally, preemptive management strategies are outlined in certain at-risk populations and after unintentional laboratory exposure.
Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration
Group, AOCS Study, Reid, Brett M. , Earp, Madalene A. , Chen, Y. Ann , Monteiro, Álvaro N.A. , Chen, Zhihua , Chenevix‐Trench, Georgia , Fasching, Peter A. , Beckmann, Matthias W. , Lambrechts, Diether , Vanderstichele, Adriaan , Niewenhuyse, Els Van, Vergote, Ignace , Rossing, Mary Anne, Chang‐Claude, Jenny, Moysich, Kirsten, Odunsi, Kunle , Goodman, Marc T. , Shvetsov, Yurii B. , Thompson, Pamela J., Dörk, Thilo , Bogdanova, Natalia , Pelttari, Liisa M. , Leminen, Arto, Edwards, Robert P., Ness, Roberta B., Kelley, Joseph L., Lester, Jenny, Jensen, Allan , Hildebrandt, Michelle, Liang, Dong , Lu, Karen H., Wu, Xifeng , Levine, Douglas A. , Bisogna, Maria, Berchuck, Andrew, Terry, Kathryn L. , Tworoger, Shelley S. , Cunningham, Julie M. , Winham, Stacey J. , Olson, Sara H. , Kiemeney, Lambertus A. , Massuger, Leon F.A.G. , Moffitt, Melissa , Le, Nhu, Kelemen, Linda E. , Lubiński, Jan , Wentzensen, Nicolas, Brinton, Louise A. , Lissowska, Jolanta , Yang, Hanna , Høgdall, Estrid , Høgdall, Claus , Lundvall, Lene, Song, Honglin , Campbell, Ian , Eccles, Diana , McNeish, Iain A. , Whittemore, Alice S. , McGuire, Valerie, Sieh, Weiva , Rothstein, Joseph H. , Phelan, Catherine M., Narod, Steven A., McLaughlin, John, Ziogas, Argyrios, Menon, Usha , Gayther, Simon A. , Ramus, Susan J. , Pearce, Celeste Leigh, Wu, Anna H. , Kupryjańczyk, Jolanta , Dansonka‐Mieszkowska, Agnieszka , Schildkraut, Joellen M. , Cheng, Jin Q. , Goode, Ellen L. , Sellers, Thomas A. , Lu, Karen H. , Lambrechts, Diether , Earp, Madalene, Cunningham, Julie, Permuth, Jennifer B. , Group, AOCS Study, Doherty, Jennifer A. , Wilkens, Lynne R. , Bützow, Ralf C. , Nevanlinna, Heli , Modugno, Francesmary , Heitz, Florian , Karlan, Beth Y. , Lester, Jenny, Kjær, Susanne K. , Giles, Graham G. , Cramer, Daniel W. , Poole, Elizabeth M. , Bandera, Elisa V. , Fridley, Brooke L. , Orlow, Irene , Bjørge, Line , Pejovic, Tanja B. , Cook, Linda S. , Brooks‐Wilson, Angela , Gronwald, Jacek , Wentzensen, Nicolas , Pharoah, Paul D.P. , Risch, Harvey A. , McLaughlin, John, Anton‐Culver, Hoda , Gentry‐Maharaj, Aleksandra , Pelttari, L M , Winham, Stacey J , Dörk, Thilo , Lambrechts, Diether , Kiemeney, Lambertus A , McNeish, Iain A , Ramus, Susan J , Tworoger, Shelley S , Vanderstichele, Adriaan , Jensen, Allan , Eccles, Diana , Menon, Usha , Monteiro, Alvaro N , Moysich, Kirsten , Lissowska, Jolanta , Campbell, Ian G , Kupryjanczyk, Jolanta , Lambrechts, Diether , Sieh, Weiva , Bogdanova, Natalia V , Chenevix-Trench, Georgia , Høgdall, Estrid , Høgdall, Claus K , Lubinski, Jan , Goodman, Marc T

Mayo Clinic

Oncotarget | July 28, 2016 | Volume: 7 | Issue: 45 | Pages: 72381-72394

10.18632/oncotarget.10546 | PMID 27911851 Get It

Early event status informs subsequent outcome in newly diagnosed follicular lymphoma
Bachy, Emmanuel , Ghesquières, Hervé , Ansell, Stephen M. , Nowakowski, Grzegorz S. , Thompson, Carrie A. , Inwards, David J. , Allmer, Cristine, Chassagne‐Clément, Catherine, Nicolas‐Virelizier, Emmanuelle , Sebban, Catherine, Lebras, Laure , Macon, William R. , Feldman, Andrew L. , Syrbu, Sergei , Traverse‐Glehan, Alexandra, Coiffier, Bertrand , Weiner, George J. , Salles, Gilles , Link, Brian K. , Maurer, Matthew J. , Sarkozy, Clémentine , Slager, Susan L. , Witzig, Thomas E. , Habermann, Thomas M. , Cerhan, James R. , Feldman, Andrew L , Link, Brian K , Salles, Gilles A , Weiner, George , Bachy, Emmanuel , Syrbu, Sergei

Mayo Clinic

American Journal of Hematology | July 28, 2016 | Volume: 91 | Issue: 11 | Pages: 1096-1101

10.1002/ajh.24492 | PMID 27465588 Get It

Recent advances in follicular lymphoma (FL) have resulted in prolongation of overall survival (OS). Here we assessed if early events as defined by event‐free survival (EFS) at 12 and 24 months from diagnosis (EFS12/EFS24) can inform subsequent OS in FL. 920 newly diagnosed grade 1‐3A FL patients enrolled on the University of Iowa/Mayo Clinic Lymphoma SPORE Molecular Epidemiology Resource (MER) from 2002‐2012 were initially evaluated. EFS was defined as time from diagnosis to progression, relapse, re‐treatment, or death due to any cause. OS was compared to age‐and‐sex‐matched survival in the general US population using standardized mortality ratios (SMR) and 95% confidence intervals (CI). We used a cohort of 412 FL patients from two Lyon, France hospital registries for independent replication. Patients who failed to achieve EFS12 had poor subsequent OS (MER SMR = 3.72, 95%CI: 2.78‐4.88; Lyon SMR = 8.74, 95%CI: 5.41‐13.36). Conversely, patients achieving EFS12 had no added mortality beyond the background population (MER SMR = 0.73, 95%CI: 0.56‐0.94, Lyon SMR = 1.02, 95%CI: 0.58‐1.65). Patients with early events after immunochemotherapy had especially poor outcomes (EFS12 failure: MER SMR = 17.63, 95%CI:11.97‐25.02, Lyon SMR = 19.10, 95%CI:9.86‐33.36; EFS24 failure: MER SMR = 13.02, 95%CI:9.31‐17.74, Lyon SMR = 7.22, 95%CI:4.13‐11.74). In a combined dataset of all patients from both cohorts, baseline FLIPI was no longer informative in EFS12 achievers. Reassessment of patient status at 12 months from diagnosis in follicular lymphoma patients, or at 24 months in patients treated with immunochemotherapy, is a strong predictor of subsequent overall survival in FL. Early event status provides a simple, clinically relevant endpoint for studies assessing outcome in FL. Am. J. Hematol. 91:1096–1101, 2016. © 2016 Wiley Periodicals, Inc.
Telomere structure and maintenance gene variants and risk of five cancer types
Karami, Sara , Pierce, Brandon L. , Nutter, Ellen L., Schumacher, Fredrick R. , Lindström, Sara , Witte, John S. , Fang, Shenying , Han, Jiali , Kraft, Peter , Song, Fengju , Hung, Rayjean J., McKay, James , Gruber, Stephen B. , Risch, Angela , Shen, Hongbing , Haiman, Christopher A. , Boardman, Lisa, Casey, Graham , Peters, Ulrike , Olama, Ali Amin Al , Berndt, Sonja I. , Brennan, Paul , Brenner, Hermann , Brinton, Louise A. , Caporaso, Neil E. , Chang‐Claude, Jenny , Cunningham, Julie M. , Easton, Douglas F. , Eeles, Rosalind A. , Eisen, Timothy, Gala, Manish , Gallinger, Steven , Gayther, Simon A. , Goode, Ellen L. , Grönberg, Henrik , Henderson, Brian E., Houlston, Richard S. , Joshi, Amit D. , Küry, Sébastien , Landi, Mari T., Muir, Kenneth , Permuth‐Wey, Jenny, Phelan, Catherine, Ramus, Susan J. , Schildkraut, Joellen M. , Slattery, Martha L. , Song, Honglin , Wentzensen, Nicolas , Zanke, Brent W., Sellers, Thomas A. , Zheng, Wei , Chatterjee, Nilanjan , TRICL, on behalf of GECCO and the GAME‐ON Network: CORECT, DRIVE, ELLIPSE, FOCI, and, Hung, Rayjean J. , Han, Younghun , Pande, Mala , Cheng, Iona C. , Rudd, James , Kote‐Jarai, Zsofia , Hunter, David J. , Hung, Rayjean J., Chanock, Stephen Jacob , Boardman, Lisa, Ulrich, Cornelia M. , Berchuck, Andrew , Bezieau, Stéphane , Chan, Andrew T. , Christiani, David C. , Marchand, Loı̈c Le , Newcomb, Polly A. , Pharoah, Paul D.P. , Potter, John D. , Risch, Harvey A. , White, Emily E. , Wiklund, Fredrik E. , Amos, Christopher I. , Doherty, Jennifer A. , TRICL, on behalf of GECCO and the GAME‐ON Network: CORECT, DRIVE, ELLIPSE, FOCI, and, Ramus, Susan J , Houlston, Richard S , Eeles, Rosalind A , Hung, Rayjean J , Muir, Kenneth , Kury, Sebastien , Brenner, Hermann , Han, Jiali , Kraft, Peter , Zheng, Wei , Risch, Angela , Shen, Hongbing

Mayo Clinic

International Journal of Cancer | July 26, 2016 | Volume: 139 | Issue: 12 | Pages: 2655-2670

10.1002/ijc.30288 | PMID 27459707 Get It

Telomeres cap chromosome ends, protecting them from degradation, double‐strand breaks, and end‐to‐end fusions. Telomeres are maintained by telomerase, a reverse transcriptase encoded by TERT, and an RNA template encoded by TERC. Loci in the TERT and adjoining CLPTM1L region are associated with risk of multiple cancers. We therefore investigated associations between variants in 22 telomere structure and maintenance gene regions and colorectal, breast, prostate, ovarian, and lung cancer risk. We performed subset‐based meta‐analyses of 204,993 directly‐measured and imputed SNPs among 61,851 cancer cases and 74,457 controls of European descent. Independent associations for SNP minor alleles were identified using sequential conditional analysis (with gene‐level p value cutoffs ≤3.08 × 10−5). Of the thirteen independent SNPs observed to be associated with cancer risk, novel findings were observed for seven loci. Across the DCLRE1B region, rs974494 and rs12144215 were inversely associated with prostate and lung cancers, and colorectal, breast, and prostate cancers, respectively. Across the TERC region, rs75316749 was positively associated with colorectal, breast, ovarian, and lung cancers. Across the DCLRE1B region, rs974404 and rs12144215 were inversely associated with prostate and lung cancers, and colorectal, breast, and prostate cancers, respectively. Near POT1, rs116895242 was inversely associated with colorectal, ovarian, and lung cancers, and RTEL1 rs34978822 was inversely associated with prostate and lung cancers. The complex association patterns in telomere‐related genes across cancer types may provide insight into mechanisms through which telomere dysfunction in different tissues influences cancer risk.
Abstract CT106: Efficacy of pertuzumab/trastuzumab/paclitaxel over standard trastuzumab/paclitaxel therapy for HER2+ breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL
Buxton, Meredith , Chia, Stephen, Veer, Laura van’t, Chien, Jo, Moulder, Stacy L. , Albain, Kathy S. , Kemmer, Kathleen, Haley, Barbara , Minton, Susan, Forero, Andres , Nanda, Rita , Korde, Larissa A. , Viscuzi, Rebecca, Rugo, Hope, Schwab, Richard B. , Symmans, Fraser, Paoloni, Melissa, Lyandres, Julia, Perlmutter, Jane , Sanil, Ashish, Berry, Don, Investigators, I-SPY 2 TRIAL, DeMichele, Angela , Wallace, Anne M. , Kaplan, Henry G. , Lang, Julie E. , Yee, Douglas , Isaacs, Claudine , Boughey, Judy C. , Elias, Anthony , Hylton, Nola M. , Hogarth, Michael A. , Yau, Christina , Esserman, Laura J. , Berry, Donald A. , Investigators, I-SPY 2 TRIAL

Mayo Clinic

Cancer Research | July 26, 2016 | Volume: 76 | Issue: 14_Supplement | Pages: CT106-CT106

10.1158/1538-7445.am2016-ct106 Get It

Abstract Background: Pathologic complete response (pCR) is an established prognostic biomarker for aggressive HER2+ breast cancer (BC). Improving pCR rates may identify new therapies that improve survival. Pertuzumab (P) has established survival benefit in the metastatic setting, and received accelerated approval in the neoadjuvant setting when combined with trastuzumab (H) and docetaxel(D) as part of a complete treatment regimen for early breast cancer. We tested its ability, when combined with standard therapy (paclitaxel, T, and H) to improve pCR (ypT0ypN0) over TH in the adaptively randomized, phase II, I-SPY 2 neoadjuvant trial. Methods: Enrolled patients (pts) had invasive BC ?2.5 cm in HER2-positive subsets. Pts were adaptively randomized to control (TH, qwk x 12) or THP (P, q3wk x 4) followed by doxorubicin/cyclophosphamide (AC) x 4 and surgery. To compare THP to TH we utilized all control pts accrued over the course of the trial, adjusting for potential differences due to time period treated, which were informed by the several other treatment arms that have been in the trial. Adaptive assignment to the experimental arms was based on current Bayesian probabilities of superiority over control. “Graduation” by signature and futility stopping were based upon Bayesian predictive probability of success in a 2-arm, N = 300 phase III randomized 1:1 trial of THP vs. TH with pCR endpoint. Results: THP met the predictive probability criterion and graduated in 3 signatures: all HER2+, HER2+/HR+, and HER2+/HR- (See Table 1). Final accrual: 44 THP and 31 TH. Safety data will be shown. Conclusions: I-SPY 2's standing platform trial efficiently evaluates agents in biomarker-defined pt subsets. THP -> AC substantially improves pCR rates over standard TH -> AC in all 3 HER2+ signatures, including HR+ and HR- subsets. APHINITY, a trial of adjuvant pertuzumab with a primary outcome of invasive disease-free survival, is ongoing. Table 1Signature*Estimated pCR Rate (95% probability interval)Signature*THPControl (TH)Probability THP Is Superior to ControlPredictive Probability of Success in Phase IIIHER2+54% (38%-70%)22% (5%-39%)99.8%96%HER2+/HR+44% (24%-63%)17% (0%-34%)99%91%HER2+/HR-74% (53%-95%)33% (6%-59%)99.8%98%*HR = Hormone Receptor Citation Format: Meredith Buxton, Angela M. DeMichele, Stephen Chia, Laura van't Veer, Jo Chien, Anne Wallace, Henry Kaplan, Julie Lang, Douglas Yee, Claudine Isaacs, Stacy Moulder, Kathy Albain, Judy Boughey, Kathleen Kemmer, Barbara Haley, Susan Minton, Andres Forero, Rita Nanda, Anthony Elias, Larissa Korde, Rebecca Viscuzi, Hope Rugo, Richard Schwab, Fraser Symmans, Melissa Paoloni, Nola Hylton, Michael Hogarth, Julia Lyandres, Jane Perlmutter, Ashish Sanil, Christina Yau, Laura Esserman, Don Berry, I-SPY 2 TRIAL Investigators. Efficacy of pertuzumab/trastuzumab/paclitaxel over standard trastuzumab/paclitaxel therapy for HER2+ breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr CT106.
Abstract CT042: Efficacy of T-DM1+pertuzumab over standard therapy for HER2+ breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL
Moulder, Stacy L. , Buxton, Meredith , Chien, Jo, Albain, Kathy S. , Kemmer, Kathleen, Haley, Barbara , Minton, Susan, Forero, Andres , Nanda, Rita , Korde, Larissa A. , Schwab, Richard B. , Melisko, Michelle , Sanil, Ashish, Paoloni, Melissa, Symmans, Fraser, Perlmutter, Jane , Lyandres, Julia, Berry, Don, Investigators, I-SPY 2 TRIAL, DeMichele, Angela , Yee, Douglas , Wallace, Anne M. , Isaacs, Claudine , Boughey, Judy C. , Lang, Julie E. , Kaplan, Henry G. , Elias, Anthony , Hogarth, Michael A. , Hylton, Nola M. , Yau, Christina , Berry, Donald A. , Esserman, Laura J. , Investigators, I-SPY 2 TRIAL

Mayo Clinic

Cancer Research | July 26, 2016 | Volume: 76 | Issue: 14_Supplement | Pages: CT042-CT042

10.1158/1538-7445.am2016-ct042 Get It

Abstract Background: Pathologic complete response (pCR) is an established prognostic biomarker for aggressive HER2+ breast cancer (BC). Improving pCR rates may identify new therapies that improve survival. T-DM1 and pertuzumab have established benefits in metastatic HER2+ BC. We tested their ability when combined, without paclitaxel, to improve pCR rates (ypT0ypN0) over standard therapy in the randomized, phase 2, I-SPY 2 neoadjuvant trial. Methods: Enrolled patients (pts) had invasive breast cancer ?2.5 cm in HER2-positive subsets. Pts were adaptively randomized to 12 wkly cycles of paclitaxel+trastuzumab (TH, control) or T-DM1+pertuzumab (T-DM1+P) without T, followed by doxorubicin/cyclophosphamide (AC) x 4 and surgery. We utilized all TH control pts accrued over the course of the trial, adjusting for potential differences due to time period treated, which were informed by the several other treatment arms that have been in the trial. Adaptive assignment to the various experimental arms in the trial was based on current Bayesian probabilities of superiority vs. control. “Graduation” by signature and futility stopping were based upon Bayesian predictive probability of success in a future 2-arm, N = 300 neoadjuvant Phase 3 randomized 1:1 trial of T-DM1+P vs. control with pCR endpoint. Results: T-DM1+P met the predictive probability criterion and graduated from I-SPY 2 in 3 signatures: all HER2+, HER2+/HR+, HER2+/HR- (Table 1). Final accrual: 52 T-DM1+P and 31 TH. Safety data will be shown. Conclusions: I-SPY 2's standing platform trial mechanism efficiently evaluates agents in biomarker-defined pt subsets. T-DM1+P (w/o T) -> AC substantially improves pCR rates over standard TH -> AC in all 3 HER2+ signatures, including HR+ and HR- subsets. These findings warrant further investigation of these agents without paclitaxel in a neoadjuvant trial powered for survival endpoints. Table 1Signature*Estimated pCR Rate (95% probability interval)Probability T-DM1+P Is Superior to Control**Predictive Probability of Success in Phase 3T-DM1+PControl (TH)HER2+52% (36%-68%)22% (5%-39%)99.5%94%HER2+/HR+46% (26%-66%)17% (0% - 34%)99.1%93%HER2+/HR-64% (39%-88%)33% (6%-59%)98%90%*HR = Hormone Receptor Citation Format: Angela M. DeMichele, Stacy Moulder, Meredith Buxton, Douglas Yee, Anne Wallace, Jo Chien, Claudine Isaacs, Kathy Albain, Judy Boughey, Kathleen Kemmer, Barbara Haley, Julie Lang, Henry Kaplan, Susan Minton, Andres Forero, Anthony Elias, Rita Nanda, Larissa Korde, Richard Schwab, Michelle Melisko, Ashish Sanil, Michael Hogarth, Nola Hylton, Melissa Paoloni, Fraser Symmans, Jane Perlmutter, Julia Lyandres, Christina Yau, Don Berry, Laura Esserman, I-SPY 2 TRIAL Investigators. Efficacy of T-DM1+pertuzumab over standard therapy for HER2+ breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr CT042.
Abstract 810: The CARRIERS consortium: Establishing refined breast cancer risk estimates in known predisposition genes
Lilyquist, Jenna , Hallberg, Emily J., Moore, Raymond M. , Nathanson, Katherine L. , Goldgar, David E. , Kraft, Peter , Hart, Steven N. , Hu, Chunling , Gnanaolivu, Rohan , Domchek, Susan M. , Weitzel, Jeffrey N. , Couch, Fergus J. , Nathanson, Katherine L

Mayo Clinic

Cancer Research | July 26, 2016 | Volume: 76 | Issue: 14_Supplement | Pages: 810-810

10.1158/1538-7445.am2016-810 Get It

Abstract Breast cancer is the most common type of cancer, and has a strong heritable component, with approximately 15 percent of new cases having family history of breast cancer. Genetic panel testing for patients with a family history of breast cancer has become a popular clinical resource. However, the risk of breast cancer associated with inactivating mutations in the predisposition genes is largely undefined, creating critical limitations in the interpretations of the results from panel testing and subsequent medical management. The Cancer Risk Estimates Related to Susceptibility Genes (CARRIERS) consortium was established to determine the risk of cancers associated with truncating mutations in the known predisposition genes and to extend these studies to the clinical classification of variants of uncertain significance (VUS) in the relevant genes. CARRIERS involves screening of approximately 30,000 population-based breast cancer cases and 30,000 study matched controls for mutations in 28 established or proposed breast cancer predisposition genes. Population-based risks for breast cancer associated with mutations in each gene will be estimated. In parallel, 10,000 breast cancer cases from moderate and high-risk breast cancer families will be similarly screened for mutations and the penetrance of the mutations in high-risk families will be estimated. Furthermore, VUS identified by mutation screening will be characterized by functional and family-based studies and models for classification of the clinical relevance of VUS in each gene will be developed. These data are expected to lead to improvements in cancer risk assessment and improved management of patients found to carry mutations or VUS in breast cancer predisposition. Citation Format: Jenna Lilyquist, Peter Kraft, Steven N. Hart, Emily J. Hallberg, Chunling Hu, Raymond Moore, Rohan Gnanaolivu, Susan M. Domchek, Jeffrey N. Weitzel, Katherine L. Nathanson, David E. Goldgar, Fergus J. Couch. The CARRIERS consortium: Establishing refined breast cancer risk estimates in known predisposition genes. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 810.